Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q3 2023 Earnings Presentation
15 slides from Bactiguard Holding Ab's earnings presentation, Oct 27, 2023
Slide 1: Interim Report Q3 2023 presentation
Interim Report Q3 2023 presentation Friday October 27, 2023 Thomas von Koch, Interim CEO
Slide 2: Transforming Bactiguard into a license focused business
Interim Report Q3 2023: Transforming Bactiguard into a license focused business with the vision to become global standard of care
Slide 3: The dangers of biofilm
The dangers of biofilm Medical devices that stay in the body more than two days – a possible danger for infection 3
Slide 4: A novel noble metal stent coating reduces in vitro platelet activation
A novel noble metal stent coating reduces in vitro platelet activation and acute in vivo thrombosis formation Published in Scientific Reports in October 2023 – available on www.bactiguard.com Joint study by Bactiguard, KI and KTH • Efficacy of the coating to reduce thrombo-inflammatory reactions and
Slide 5: Biggest strategic shift in Bactiguard's history
Biggest strategic shift in Bactiguard’s history Key priorities rest of 2023 and 2024 License R&D and BIP portfolio coating development - strengthen organization - outsourcing discussions - double down on - institutionalize - orderly transition and gradual current partnerships - Billy Södervall Acade
Slide 6: A vision firmly connected to Bactiguard's strategy
A vision firmly connected to Bactiguard’s strategy Vision (what we strive to become) “to be the global standard of care for preventing medical device related infections” Mission (what we do to reach our vision) “by being the premier partner for leading medtech companies, joining forces to redefine h
Slide 7: A license focused business model – effective full-year 2023
A license focused business model – effective full-year 2023 “Customer acquisition costs” Revenue-generating partnerships development partners transfer agreement Initial discussion Negotiations Prospects Material Application Exclusivity partners License partners development partners no products in ma
Slide 8: Financials Q3 2023 (Q3 2022) and key events
Financials Q3 2023 (Q3 2022) and key events Transformation into a license focused business with the vision to become global standard of care Revenues EBITDA Net Loss Operating cash flow 49 (66) SEKm -9.5 (2.5) SEKm -24.6 (-8.5) SEKm -35.7 (3.1) SEKm Key events Q3 and events after the period • Profit
Slide 9: Financial overview
Financial overview Amounts in SEKm 2023 2022 2023 2022 • Total revenue YTD decrease of 11% Jul-Sep Jul-Sep Jan-Sep Jan-Sep ‒ License -26% ‒ BPP 28% Total revenues 49,5 66,2 161,8 181,3 - License 20,8 42,4 85,0 115,1 • Cost YTD impacted by Q2 -42 SEKm - BPP 24,6 16,3 60,3 47,2 adjustment Total cost -
Slide 10: Rolling 12-months revenues
Rolling 12-months revenues Note - “old” revenue format 250 Recurring license revenues 80 60 200 • Key driver BD and initial 40 contributions from Zimmer Biomet (trauma) 20 150 Non-recurring license revenues 0 100 • Zimmer Biomet (broader -20 portfolio) and Dentsply -40 50 BPP sales -60 0 -80 • BIP s
Slide 11: Q3 2023 highlights – Licensing business
Q3 2023 highlights – Licensing business Recurring revenues Non-recurring revenues Revenues Q3 2023 Revenues Q3 2023 9.2 (34.8) SEKm 11.6 (7.6) SEKm -74% 53% Orthopedics (trauma) Orthopedics (broader portfolio) • ZNN Bactiguard roll-out across • Process taking longer than expected - • Largest license
Slide 12: Q3 2023 highlights and status – BPP
Q3 2023 highlights and status – BPP BPP (Bactiguard Product Portfolio) Revenues Q3 2023 24.6 (16.3) SEKm 51% • Despite strong BIP sales of 7.0 SEKm in Q3, profitability issues remain • Outsourcing discussions intense with current and new partners for CVCs, ETTs, and Foleys • Wound Management not aff
Slide 13: Updated financial targets
Updated financial targets Mid-term expectations given new strategy and license focused business model Application areas generating Profitability Growth license revenues have at least 10 application areas deliver an EBITDA of SEK 500 deliver net sales in excess of in license partnerships with million
Slide 14: Q&A
Q&A Q&A to champion a healthier world by preventing infections 14
Slide 15: Questions & Answers
Questions & Answers Interim Report Q3 2023 Thomas von Koch Carin Jakobson Interim CEO CFO 15